A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

  1. Hajek, R.
  2. Pour, L.
  3. Ozcan, M.
  4. Martin Sánchez, J.
  5. García Sanz, R.
  6. Anagnostopoulos, A.
  7. Oriol, A.
  8. Cascavilla, N.
  9. Terjung, A.
  10. Lee, Y.
  11. Briso, E.M.
  12. Dobkowska, E.
  13. Hauns, B.
  14. Špička, I.
Aldizkaria:
European Journal of Haematology

ISSN: 1600-0609,  0902-4441

Argitalpen urtea: 2020

Alea: 104

Zenbakia: 5

Orrialdeak: 435-442

Mota: Artikulua

DOI: 10.1111/EJH.13377 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus